差异表达miRNA在胰腺癌预后判断中的价值

doi:10.3969/j.issn.1004-616x.2019.03.001

Abstract

Abstract: OBJECTIVE:To analyze associations between differentially expressed miRNAs and development of pancreatic cancers, and to screen biomarkers which might be related to prognosis of pancreatic cancers. METHODS:Data of GSE32678 and GSE71533 datasets in Gene Expression Omnibus (GEO) were downloaded to screen differentially expressed miRNAs by using R language and the intersection of the three data sets were taken. Bioinformatics analysis tool was used to predict target genes of overlapping miRNAs, to perform functional analysis on the target genes,and to construct a protein interaction network (PPI),a miRNA-mRNA network,and a miRNA-mRNA-pathway network. The markers which were related to prognosis of pancreatic cancers were screened by using the expression and prognosis data of miRNAs of pancreatic cancer samples in the Cancer Genome Atlas (TCGA). RESULTS:A total of 22 overlapping miRNAs were screened,and hsamiR-30a-5p,hsa-miR-551a,and hsa-miR-375 were closely related to the prognosis of pancreatic cancer. The core miRNAs in the miRNA-mRNA network were hsa-miR-125b-5p,hsa-miR-221-3p,hsa-miR-31-5p, hsa-miR-222-3p and hsa-miR-10a-5p. CONCLUSION:Analysis of data of pancreatic cancers in the GEO and TCGA databases reveal that hsa-miR-30a-5p,hsa-miR-551a,and hsa-miR-375 significantly affected the prognosis of pancreatic cancers and could be used as markers for prognosis.

Key words: pancreatic cancer, miRNA, prognosis, GEO database, TCGA database

CLC Number:

R318.04

GAO Jie, ZHANG Xiao, WEI Chao. Involvement of differentially expressed miRNA in prognosis of pancreatic cancers[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 173-179.

References

[1] CHEN W, ZHENG R, ZHANG S, et al. Report of incidence and mortality in China cancer registries, 2009[J]. Chin J Cancer Res,2013,25(1):10-21.
[2] TORRE L A,FREDDIE B,SIEGEL R L,et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):69-90.
[3] YANG W, HUA Z, GAO X, et al. Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma[J]. Oncotarget,2016,7(18):26070-26086.
[4] SONJA G, TIBOR S, HELMUT F, et al. Preoperative/neoadjuvant therapy in pancreatic cancer:a systematic review and meta-analysis of response and resection percentages[J]. PLoS Med,2010,7(4):e1000267.
[5] 魏超,张晓,高杰. 长链非编码RNA与mRNA在胰腺癌中的差异表达及其预后价值[J]. 癌变·畸变·突变,2019, 31(2):119-126.
[6] RAHELEH A,ULF S,MICHAEL L,et al. MicroRNAmRNA interactions in colorectal cancer and their role in tumor progression[J]. Genes Chromosomes Cancer, 2015, 54(3):129-141.
[7] WENBIN Y,QING L,CHUNG-KWUN AMY W,et al. The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation[J]. PLoS One,2008,3(3):e1719.
[8] SCHETTER A J, SUET YI L, SOHN J J, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma[J]. JAMA,2008,299(4):425.
[9] YANG S, SUI J, LIANG G. Diagnosis value of aberrantly expressed microRNA profiles in lung squamous cell carcinoma:a study based on the Cancer Genome Atlas[J]. Peer J,2017,5(2):e4101.
[10] YOSHITO T, HIDETOSHI E, HIROAKI N, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J]. Sichuan Med J,2012,56(1):167-175.
[11] UEDA T, VOLINIA S, OKUMURA H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer:a microRNA expression analysis[J]. Lancet Oncol,2010,11(2):136-146.
[12] DONAHUE T R, TRAN L M, HILL R, et al. Integrative survival-based molecular profiling of human pancreatic cancer[J]. Clin Cancer Res,2012,18(5):1310-1352.
[13] BAUER A S, KELLER A, COSTELLO E, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue[J]. PLoS One,2012,7(4):e34151.
[14] WEI H D, SHERMAN B T, QINA T, et al. DAVID bioinformatics resources:expanded annotation database and novel algorithms to better extract biology from large gene lists[J]. Nucleic Acids Res,2007,35(2):W169-W175.
[15] SZKLARCZYK D, MORRIS J H, COOK H, et al. The STRING database in 2017:quality-controlled proteinprotein association networks, made broadly accessible[J]. Nucleic Acids Res,2017,45:D362-D368.
[16] SHANNON P, MARKIEL A, OZIER O, et al. Cytoscape:a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003,13(11):2498-2504.
[17] 魏巧. 食管鳞癌miRNA与全基因组表达谱及其调控网络的研究[D]. 上海:复旦大学,2013.
[18] VINCENT A, HERMAN J, SCHULICK R, et al. Pancreatic cancer[J]. Lancet,2011,378(9791):607-620.
[19] CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China,2015[J]. CA Cancer J Clin,2016,66(2):115-132.
[20] YANG G Y, WAGNER T D, FUSS M, et al. Multimodality approaches for pancreatic cancer[J]. CA Cancer J Clin,2010,55(6):352-367.
[21] RABOFSKI J L, VASHIST Y K, KALININA T, et al. HSP90 als Therapie-Target bei Gemcitabine und 5-Fluorouracil resistentem Pankreaskarzinom[M]. Heidelberg:Springer Berlin Heidelberg,2010:67-68.
[22] YONG S L, DUTTA A. MicroRNAs in cancer[J]. Annu Rev Pathol Mech Dis,2009,4(4):199-227.
[23] YUAN W, TANG W, XIE Y, et al. New combined microRNA and protein plasmatic biomarker panel for pancreatic cancer[J]. Oncotarget, 2016, 7(48):80033-80045.
[24] ZHANG Z,PAN B,LV S,et al. Integrating microRNA expression profiling studies to systematically evaluate the diagnostic value of microRNAs in pancreatic cancer and validate their prognostic significance with the Cancer Genome Atlas Data[J]. Cell Physiol Biochem, 2018, 49(2):678-695.
[25] DOU D, YANG S, LIN Y, et al. An eight-miRNA signature expression-based risk scoring system for prediction of survival in pancreatic adenocarcinoma[J]. Cancer Biomark,2018,23(1):79-93.
[26] LI C H, XIAO Z, HUNG-MAN T J, et al. EZH2 coupled with HOTAIR to silence microRNA-34a by the induction of heterochromatin formation in human pancreatic ductal adenocarcinoma[J]. Int J Cancer, 2016, 140(1):120-129.
[27] TURASHVILI G,LIGHTBODY E D,TYRYSHKIN K,et al. Novel prognostic and predictive microRNA targets for triple-negative breast cancer[J]. FASEB J,2018,32(11):201800120R.
[28] YANG D, YAN R, XIN Z, et al. Deregulation of microRNA-375 inhibits cancer proliferation migration and chemosensitivity in pancreatic cancer through the association of HOXB3[J]. Am J Transl Res,2016,8(3):1551-1559.
[29] ZHOU J, SONG S, CEN J, et al. MicroRNA-375 is downregulated in pancreatic cancer and inhibits cell proliferation in vitro[J]. Oncol Res,2012,20(5/6):197.
[30] TAO J, CONG H, WANG H, et al. MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1[J]. Biochem Biophys Res Commun, 2018,503(2):1092-1097.
[31] WANG Y,QIU C,LU N,et al. FOXD1 is targeted by miR-30a-5p and miR-200a-5p and suppresses the proliferation of human ovarian carcinoma cells by promoting p21 expression in a p53-independent manner[J]. Int J Oncol,2018,52(6):2130-2142.
[32] LI Z, CAO Y, JIE Z, et al. miR-495 and miR-551a inhibit the migration and invasion of human gastric cancer cells by directly interacting with PRL-3[J]. Cancer Lett, 2012,323(1):41-47.
[33] 吴孟闱. miR-125b-5p参与胰腺癌侵袭转移分子机制的研究[D]. 沈阳:中国医科大学,2018.
[34] ZHOU C, MA J, HUANG L, et al. Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1[J]. Oncogene,2019,38(8):1256-1268.
[35] PENG H,WANG L,SU Q,et al. MiR-31-5p promotes the cell growth, migration and invasion of colorectal cancer cells by targeting NUMB[J]. Biomed Pharmacother, 2019,109:208-216.
[36] CHANG Y, WENG S, YANG S, et al. A ThreemicroRNA signature as a potential biomarker for the early detection of oral cancer[J]. Int J Mol Sci, 2018, 19(3):758-775.
[37] XIONG G, HUANG H, FENG M, et al. MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma[J]. Exp Clin Cancer Res, 2018,37(1):76-91.
[38] RAVI R K,WEBER E,MCMAHON M,et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells[J]. J Clin Invest,1998(1):153-159.
[39] DAVIS R J. Signal transduction by the JNK group of MAP kinases[J]. Cell,2000,103(2):239-252.
[40] POTENTE M, URBICH C, SASAKI K, et al. Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization[J]. J Clin Invest, 2005, 115(9):2382-2392.
[41] BOISSIER P, HUYNH-DO U. The guanine nucleotide exchange factor Tiam1:A Janus-faced molecule in cellular signaling[J]. Cell Signal,2014,26(3):483-491.
[42] HOCKENBERY D M, ZUTTER M, HICKEY W, et al. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death[J]. Proc Natl Acad Sci USA,1991,88(16):6961-6965.

Involvement of differentially expressed miRNA in prognosis of pancreatic cancers

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[2]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[3]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[4]	JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.
[5]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[6]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[7]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[8]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[9]	DU Qiang, YAO Yiyong, ZENG Gang. Expression and clinical significance of ASPM in lung adenocarcinoma according to the TCGA database [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 457-463.
[10]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[11]	SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.
[12]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[13]	GUO Xiujuan, DU Yanyan, YAN Xi, ZHAO Xuetao, HAN Lina, WU Yipeng, WANG Xuexiao, MA Ming. Expression and clinical significance of CREB in esophageal squamous cell carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 387-390,394.
[14]	YANG Li, ZHANG Mengxian, ZHANG Wei, XIONG Yingyou, CHEN Shiyong, FANG Chengxiang. Data mining to investigate expression and significance of aurora kinase A in esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 221-228.
[15]	LI Yuwen, LI Chen, FENG Jiangbin, FAN Li, LIU Jianxiang, LIU Qingjie, TIAN Mei. Effect of UVB irradiation on TGF-β1,and expression of miRNA and cyclooxygenase-2 in human keratinocytes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(5): 341-346.